Ferretti Francesca, Cannatelli Rosanna, Monico Maria Camilla, Maconi Giovanni, Ardizzone Sandro
Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, "Luigi Sacco" University Hospital, 20157 Milan, Italy.
J Clin Med. 2022 Apr 20;11(9):2302. doi: 10.3390/jcm11092302.
The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications such as dysplasia and colorectal carcinoma and improve quality of life. Although a curative medical treatment for UC has not yet been found, new therapeutic strategies addressing specific pathogenetic mechanisms of disease are emerging. Notwithstanding these novel therapies, non-biological conventional drugs remain a mainstay of treatment. The aim of this review is to summarize current therapeutic strategies used as treatment for ulcerative colitis and to briefly focus on emerging therapeutic strategies, including novel biologic therapies and small molecules. To date, multiple therapeutic approaches can be adopted in UC and the range of available compounds is constantly increasing. In this era, the realization of well-designed comparative clinical trials, as well as the definition of specific therapeutic models, would be strongly suggested in order to achieve personalized management for UC patients.
溃疡性结肠炎(UC)治疗的主要目标是诱导并维持疾病的临床和内镜缓解,降低发育异常和结直肠癌等并发症的发生率,并提高生活质量。尽管尚未找到治愈UC的药物治疗方法,但针对疾病特定发病机制的新治疗策略正在不断涌现。尽管有这些新疗法,但非生物传统药物仍然是治疗的主要手段。本综述的目的是总结目前用于治疗溃疡性结肠炎的治疗策略,并简要关注新兴的治疗策略,包括新型生物疗法和小分子药物。迄今为止,UC治疗可采用多种治疗方法,可用化合物的范围也在不断增加。在这个时代,强烈建议开展设计良好的对比临床试验,并明确具体的治疗模式,以实现对UC患者的个性化管理。